Efficacy and safety of Wuling capsule for the treatment of mild depression in patients with early Parkinson’s disease in China: a randomized clinical trial

Abstract Background Depression is a prevalent non-motor symptom of Parkinson’s disease (PD) that significantly impacts patients’ quality of life. The Wuling capsule, a traditional Chinese medicine, is often utilized for treating depression, and this herbal medicine has been used to treat those PD pa...

Full description

Saved in:
Bibliographic Details
Main Authors: Yuwen Zhao, Lin Li, Dongya Huang, Wentao Li, Qiuyan Zhao, Huiqin Liu, Ran Xiong, Meijuan Liu, Jing Gan, Na Wu, Zhihua Liu, Xinxin Chen, Shizheng Zhang, Huina Feng, Jinfeng Lu, Xiaodan Chen, Yu Zhang, Xiaohui Zhao, Zhenguo Liu
Format: Article
Language:English
Published: BMC 2025-07-01
Series:BMC Complementary Medicine and Therapies
Subjects:
Online Access:https://doi.org/10.1186/s12906-025-04991-y
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849767135824314368
author Yuwen Zhao
Lin Li
Dongya Huang
Wentao Li
Qiuyan Zhao
Huiqin Liu
Ran Xiong
Meijuan Liu
Jing Gan
Na Wu
Zhihua Liu
Xinxin Chen
Shizheng Zhang
Huina Feng
Jinfeng Lu
Xiaodan Chen
Yu Zhang
Xiaohui Zhao
Zhenguo Liu
author_facet Yuwen Zhao
Lin Li
Dongya Huang
Wentao Li
Qiuyan Zhao
Huiqin Liu
Ran Xiong
Meijuan Liu
Jing Gan
Na Wu
Zhihua Liu
Xinxin Chen
Shizheng Zhang
Huina Feng
Jinfeng Lu
Xiaodan Chen
Yu Zhang
Xiaohui Zhao
Zhenguo Liu
author_sort Yuwen Zhao
collection DOAJ
description Abstract Background Depression is a prevalent non-motor symptom of Parkinson’s disease (PD) that significantly impacts patients’ quality of life. The Wuling capsule, a traditional Chinese medicine, is often utilized for treating depression, and this herbal medicine has been used to treat those PD patients with depression. This study aims to assess the efficacy and safety of Wuling capsule in treating mild depression in patients with early PD. Methods This multicenter, double-blind, placebo-controlled randomized clinical trial included 160 patients with early PD who presented with a Hamilton Rating Scale for Depression (HAMD) score between 8 and 17 at the time of admission. The trial was conducted across five hospitals in China from December 2021 to March 2024. Eligible patients were randomly assigned to receive either Wuling capsule (0.99 g orally three times daily) or a placebo (0.99 g orally three times daily) for a duration of 12 weeks. Additional treatment according to established clinical guidelines.The primary outcome measure was the change in HAMD score. All statistical analyses were conducted on an intention-to-treat population. Results After 12 weeks of treatment, among the 160 patients with early PD and depression, 80 were assigned to the Wuling capsule group and 80 to the placebo group, with the median age of 70.5 (IQR,67.00–75.00) years and 77 (48.13%) were male. Patients in the Wuling capsule group demonstrated significantly greater reductions in depression severity compared to the placebo group at multiple time points: week 4 (difference, − 1.21 [95% CI, -2.38 to -0.04; P = 0.042]), week 8 (difference, − 1.41 [95% CI, -2.81 to -0.02; P = 0.047]), and week 12 (difference, − 1.46 [95% CI, -2.89 to -0.04; P = 0.044]). Adverse events were reported in 3 of 80 patients (3.75%) in the Wuling capsule group and 3 of 80 patients (3.75%) in the control group (P = 1), indicating no significant difference. Conclusion This randomized clinical trial demonstrated that treatment with Wuling capsule over a 12-week period effectively reduced HAMD score in patients with mild depression associated with PD and the treatment was well tolerated. Trial registration Chinese Clinical Trial Registry; registration number: ChiCTR2100046195; prospectively registered on May 9th, 2021.
format Article
id doaj-art-5a42fa4e6cc14cb5aaf02473026dc76f
institution DOAJ
issn 2662-7671
language English
publishDate 2025-07-01
publisher BMC
record_format Article
series BMC Complementary Medicine and Therapies
spelling doaj-art-5a42fa4e6cc14cb5aaf02473026dc76f2025-08-20T03:04:18ZengBMCBMC Complementary Medicine and Therapies2662-76712025-07-0125111010.1186/s12906-025-04991-yEfficacy and safety of Wuling capsule for the treatment of mild depression in patients with early Parkinson’s disease in China: a randomized clinical trialYuwen Zhao0Lin Li1Dongya Huang2Wentao Li3Qiuyan Zhao4Huiqin Liu5Ran Xiong6Meijuan Liu7Jing Gan8Na Wu9Zhihua Liu10Xinxin Chen11Shizheng Zhang12Huina Feng13Jinfeng Lu14Xiaodan Chen15Yu Zhang16Xiaohui Zhao17Zhenguo Liu18Department of Neurology, Xinhua Hospital, Shanghai Jiao Tong University School of MedicineDepartment of Neurology, Xinhua Hospital, Shanghai Jiao Tong University School of MedicineDepartment of Neurology, East Hospital, Tongji University School of MedicineDepartment of neurology, Shanghai municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese MedicineDepartment of Neurology, The Fourth Division Hospital of Xinjiang Production and Construction CorpsDepartment of Neurology, Shanghai Pudong New Area People’s HospitalDepartment of Neurology, East Hospital, Tongji University School of MedicineDepartment of neurology, Shanghai municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese MedicineDepartment of Neurology, Xinhua Hospital, Shanghai Jiao Tong University School of MedicineDepartment of Neurology, Xinhua Hospital, Shanghai Jiao Tong University School of MedicineDepartment of Neurology, Xinhua Hospital, Shanghai Jiao Tong University School of MedicineDepartment of Neurology, Wenzhou Central HospitalDepartment of Neurology, Wenzhou Central HospitalDepartment of Neurology, Hangzhou Linping Hospital of Traditional Chinese MedicineDepartment of Neurology, Hangzhou Linping Hospital of Traditional Chinese MedicineTraditional Chinese Medical Hospital of ZhujiDepartment of Neurology, Xinhua Hospital, Shanghai Jiao Tong University School of MedicineDepartment of Neurology, Shanghai Pudong New Area People’s HospitalDepartment of Neurology, Xinhua Hospital, Shanghai Jiao Tong University School of MedicineAbstract Background Depression is a prevalent non-motor symptom of Parkinson’s disease (PD) that significantly impacts patients’ quality of life. The Wuling capsule, a traditional Chinese medicine, is often utilized for treating depression, and this herbal medicine has been used to treat those PD patients with depression. This study aims to assess the efficacy and safety of Wuling capsule in treating mild depression in patients with early PD. Methods This multicenter, double-blind, placebo-controlled randomized clinical trial included 160 patients with early PD who presented with a Hamilton Rating Scale for Depression (HAMD) score between 8 and 17 at the time of admission. The trial was conducted across five hospitals in China from December 2021 to March 2024. Eligible patients were randomly assigned to receive either Wuling capsule (0.99 g orally three times daily) or a placebo (0.99 g orally three times daily) for a duration of 12 weeks. Additional treatment according to established clinical guidelines.The primary outcome measure was the change in HAMD score. All statistical analyses were conducted on an intention-to-treat population. Results After 12 weeks of treatment, among the 160 patients with early PD and depression, 80 were assigned to the Wuling capsule group and 80 to the placebo group, with the median age of 70.5 (IQR,67.00–75.00) years and 77 (48.13%) were male. Patients in the Wuling capsule group demonstrated significantly greater reductions in depression severity compared to the placebo group at multiple time points: week 4 (difference, − 1.21 [95% CI, -2.38 to -0.04; P = 0.042]), week 8 (difference, − 1.41 [95% CI, -2.81 to -0.02; P = 0.047]), and week 12 (difference, − 1.46 [95% CI, -2.89 to -0.04; P = 0.044]). Adverse events were reported in 3 of 80 patients (3.75%) in the Wuling capsule group and 3 of 80 patients (3.75%) in the control group (P = 1), indicating no significant difference. Conclusion This randomized clinical trial demonstrated that treatment with Wuling capsule over a 12-week period effectively reduced HAMD score in patients with mild depression associated with PD and the treatment was well tolerated. Trial registration Chinese Clinical Trial Registry; registration number: ChiCTR2100046195; prospectively registered on May 9th, 2021.https://doi.org/10.1186/s12906-025-04991-yParkinson’s diseaseWuling capsuleDepression
spellingShingle Yuwen Zhao
Lin Li
Dongya Huang
Wentao Li
Qiuyan Zhao
Huiqin Liu
Ran Xiong
Meijuan Liu
Jing Gan
Na Wu
Zhihua Liu
Xinxin Chen
Shizheng Zhang
Huina Feng
Jinfeng Lu
Xiaodan Chen
Yu Zhang
Xiaohui Zhao
Zhenguo Liu
Efficacy and safety of Wuling capsule for the treatment of mild depression in patients with early Parkinson’s disease in China: a randomized clinical trial
BMC Complementary Medicine and Therapies
Parkinson’s disease
Wuling capsule
Depression
title Efficacy and safety of Wuling capsule for the treatment of mild depression in patients with early Parkinson’s disease in China: a randomized clinical trial
title_full Efficacy and safety of Wuling capsule for the treatment of mild depression in patients with early Parkinson’s disease in China: a randomized clinical trial
title_fullStr Efficacy and safety of Wuling capsule for the treatment of mild depression in patients with early Parkinson’s disease in China: a randomized clinical trial
title_full_unstemmed Efficacy and safety of Wuling capsule for the treatment of mild depression in patients with early Parkinson’s disease in China: a randomized clinical trial
title_short Efficacy and safety of Wuling capsule for the treatment of mild depression in patients with early Parkinson’s disease in China: a randomized clinical trial
title_sort efficacy and safety of wuling capsule for the treatment of mild depression in patients with early parkinson s disease in china a randomized clinical trial
topic Parkinson’s disease
Wuling capsule
Depression
url https://doi.org/10.1186/s12906-025-04991-y
work_keys_str_mv AT yuwenzhao efficacyandsafetyofwulingcapsuleforthetreatmentofmilddepressioninpatientswithearlyparkinsonsdiseaseinchinaarandomizedclinicaltrial
AT linli efficacyandsafetyofwulingcapsuleforthetreatmentofmilddepressioninpatientswithearlyparkinsonsdiseaseinchinaarandomizedclinicaltrial
AT dongyahuang efficacyandsafetyofwulingcapsuleforthetreatmentofmilddepressioninpatientswithearlyparkinsonsdiseaseinchinaarandomizedclinicaltrial
AT wentaoli efficacyandsafetyofwulingcapsuleforthetreatmentofmilddepressioninpatientswithearlyparkinsonsdiseaseinchinaarandomizedclinicaltrial
AT qiuyanzhao efficacyandsafetyofwulingcapsuleforthetreatmentofmilddepressioninpatientswithearlyparkinsonsdiseaseinchinaarandomizedclinicaltrial
AT huiqinliu efficacyandsafetyofwulingcapsuleforthetreatmentofmilddepressioninpatientswithearlyparkinsonsdiseaseinchinaarandomizedclinicaltrial
AT ranxiong efficacyandsafetyofwulingcapsuleforthetreatmentofmilddepressioninpatientswithearlyparkinsonsdiseaseinchinaarandomizedclinicaltrial
AT meijuanliu efficacyandsafetyofwulingcapsuleforthetreatmentofmilddepressioninpatientswithearlyparkinsonsdiseaseinchinaarandomizedclinicaltrial
AT jinggan efficacyandsafetyofwulingcapsuleforthetreatmentofmilddepressioninpatientswithearlyparkinsonsdiseaseinchinaarandomizedclinicaltrial
AT nawu efficacyandsafetyofwulingcapsuleforthetreatmentofmilddepressioninpatientswithearlyparkinsonsdiseaseinchinaarandomizedclinicaltrial
AT zhihualiu efficacyandsafetyofwulingcapsuleforthetreatmentofmilddepressioninpatientswithearlyparkinsonsdiseaseinchinaarandomizedclinicaltrial
AT xinxinchen efficacyandsafetyofwulingcapsuleforthetreatmentofmilddepressioninpatientswithearlyparkinsonsdiseaseinchinaarandomizedclinicaltrial
AT shizhengzhang efficacyandsafetyofwulingcapsuleforthetreatmentofmilddepressioninpatientswithearlyparkinsonsdiseaseinchinaarandomizedclinicaltrial
AT huinafeng efficacyandsafetyofwulingcapsuleforthetreatmentofmilddepressioninpatientswithearlyparkinsonsdiseaseinchinaarandomizedclinicaltrial
AT jinfenglu efficacyandsafetyofwulingcapsuleforthetreatmentofmilddepressioninpatientswithearlyparkinsonsdiseaseinchinaarandomizedclinicaltrial
AT xiaodanchen efficacyandsafetyofwulingcapsuleforthetreatmentofmilddepressioninpatientswithearlyparkinsonsdiseaseinchinaarandomizedclinicaltrial
AT yuzhang efficacyandsafetyofwulingcapsuleforthetreatmentofmilddepressioninpatientswithearlyparkinsonsdiseaseinchinaarandomizedclinicaltrial
AT xiaohuizhao efficacyandsafetyofwulingcapsuleforthetreatmentofmilddepressioninpatientswithearlyparkinsonsdiseaseinchinaarandomizedclinicaltrial
AT zhenguoliu efficacyandsafetyofwulingcapsuleforthetreatmentofmilddepressioninpatientswithearlyparkinsonsdiseaseinchinaarandomizedclinicaltrial